By Matthew Bultman ( April 10, 2015, 2:52 PM EDT) -- Attorneys for certain buyers of organ transplant anti-rejection drug Prograf sought $34 million in fees and expenses Thursday, three months after reaching a $98 million deal with Astellas Pharma US Inc. over allegations it delayed entry of a generic form of the immunosuppressant....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.